Opdualag 80 mg/240 mg
As listed in the register: Opdualag 80 mg/240 mg, concentraat voor oplossing voor infusie
80 mg + 240 mg · concentraat voor oplossing voor infusie
- Prescription only
- Cancer treatments and immune-system medicines
- Active substance
- Nivolumab + Relatlimab
- Made by
- Bristol-Myers Squibb Pharma EEIG
- Source
- Official label
Quoted from the official source. Not yet reviewed by Mediclarum — the leaflet in your pack is authoritative.
What it is for
Mediclarum has not yet retrieved and stored the official label for this product, so none of its text is shown here. Open the official leaflet
Same active substance, strength and form in other countries
Matched on active substance, strength and kind of form only. This is not a statement that the products are equivalent or interchangeable: other ingredients, release and approved uses can differ — ask a pharmacist before swapping.
Medicine passport: one printable page to show a pharmacist abroad
European UnionNo exact match for this strength and form
SpainNo exact match for this strength and form
CanadaNo exact match for this strength and form
SwitzerlandNo exact match for this strength and form
Details
| Made by | Bristol-Myers Squibb Pharma EEIG |
|---|---|
| Active substance | Nivolumab + Relatlimab |
| Used in | Cancer treatments and immune-system medicines |
| Strength | 80 mg + 240 mg |
| Form | concentraat voor oplossing voor infusie |
| Classification | L01FY02 · Cancer treatments and immune-system medicines |
| Route | intraveneus gebruik |
| Dispensing (as stated by the register) | Uitsluitend recept |
| Name in the register | Opdualag 80 mg/240 mg, concentraat voor oplossing voor infusie |
| RVG | EU/1/22/1679 |
Source: Geneesmiddeleninformatiebank · 2026-09-30 · not reviewed by a clinician
Bron: College ter Beoordeling van Geneesmiddelen (CBG). De Rijksoverheid is het niet automatisch eens met de inhoud van deze site. Reuse terms: CC0 1.0 (CBG website).